Abstract
RET fusion has been identified as an oncogenic driver in approximately 1-2% of patients with NSCLC. Pralsetinib is a highly potent and selective inhibitor of RET and oncogenic RET alterations. ARROW is a phase I/II, open-label, and first-in-human study to evaluate the safety and antineoplastic activity of pralsetinib in a variety of advanced RET altered solid tumors including NSCLC. Previously we reported the efficacy and safety results of pralsetinib in a cohort of Chinese patients with RET fusion+ NSCLC after platinum-based chemotherapy at WCLC 2020.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
